Halozyme Therapeutics | HALO - Ordinary Share Capital


Halozyme Therapeutics reported $117.52M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.28M 241K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Amarin USD 20.8M 28K Sep/2025
Amgen USD 538M 300K Sep/2025
Baxter International USD 683M 0 Dec/2024
Cytokinetics USD 122.12M 2.52M Sep/2025
DBV Technologies USD 11.65M 1000 Mar/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Halozyme Therapeutics USD 117.52M 98K Sep/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
MannKind USD 307.03M 303.99M Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
United Therapeutics USD 42.9M 42.1M Sep/2025